Equities research analysts forecast that Chemed Co. (NYSE:CHE) will announce sales of $423.56 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Chemed’s earnings, with the highest sales estimate coming in at $425.40 million and the lowest estimate coming in at $421.72 million. Chemed reported sales of $403.48 million during the same quarter last year, which would indicate a positive year over year growth rate of 5%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, February 14th.

On average, analysts expect that Chemed will report full-year sales of $423.56 million for the current fiscal year. For the next financial year, analysts anticipate that the firm will post sales of $1.73 billion per share, with estimates ranging from $1.69 billion to $1.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Chemed.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to the consensus estimate of $414.34 million. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.73 earnings per share.

Several brokerages recently issued reports on CHE. ValuEngine downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective on the stock in a research note on Thursday, November 2nd. Royal Bank of Canada upped their price objective on shares of Chemed to $232.00 and gave the company a “sector perform” rating in a research note on Tuesday, October 31st. TheStreet raised shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Finally, Oppenheimer upped their price objective on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $236.00.

In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $250.00, for a total transaction of $250,000.00. Following the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Naomi C. Dallob sold 750 shares of the stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total transaction of $166,567.50. Following the transaction, the vice president now directly owns 9,097 shares in the company, valued at approximately $2,020,352.73. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,679 shares of company stock worth $10,628,959. 4.90% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of CHE. Acrospire Investment Management LLC acquired a new stake in shares of Chemed in the second quarter worth $120,000. IFP Advisors Inc increased its position in shares of Chemed by 1,504.5% in the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Chemed by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares in the last quarter. MCF Advisors LLC acquired a new stake in shares of Chemed in the third quarter worth $152,000. Finally, Magnetar Financial LLC acquired a new stake in shares of Chemed in the third quarter worth $207,000. 97.71% of the stock is currently owned by institutional investors.

Chemed (CHE) opened at $263.97 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The stock has a market cap of $4,176.87, a P/E ratio of 58.66, a P/E/G ratio of 2.94 and a beta of 1.16. Chemed has a one year low of $163.50 and a one year high of $266.31.

ILLEGAL ACTIVITY WARNING: “$423.56 Million in Sales Expected for Chemed Co. (CHE) This Quarter” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/423-56-million-in-sales-expected-for-chemed-co-che-this-quarter/1811891.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Get a free copy of the Zacks research report on Chemed (CHE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.